Advertisement
Perspectives

Newer insulins in diabetes and their clinical utility

Ashish Munsif, Roger Chen

Figures

© moyo studios/istockphoto model used for illustrative purposes only
© moyo studios/istockphoto model used for illustrative purposes only

Abstract

Over the past few years, four insulins have been listed on the PBS, providing more options to potentially optimise glycaemic control in patients with diabetes. These insulins are insulin glargine 300 units/mL, insulin degludec 70%/ insulin aspart 30%, ultra-fast-acting insulin aspart and insulin lispro 200 units/mL.

Key Points

  • Four insulins have in recent years been listed on the PBS, providing clinicians and patients with more options to potentially optimise glycaemic control.
  • These insulins are insulin glargine 300 units/mL (Toujeo), insulin degludec 70%/insulin aspart 30% (Ryzodeg 70/30), ultra-fast-acting insulin aspart (Fiasp) and insulin lispro 200 units/mL (Humalog U200).
  • Potential advantages of some of these insulins include lower rates of nocturnal hypoglycaemia and more flexibility in dosing times.
  • Regardless of the insulin used, assessment of diet and physical activity are crucial for all patients with diabetes. Initiation or changes to the type and/or regimen of insulin should preferably occur in a multidisciplinary setting with input from medical specialists, diabetes educators and dietitians.

Figures

© moyo studios/istockphoto model used for illustrative purposes only
© moyo studios/istockphoto model used for illustrative purposes only